Live Breaking News & Updates on Philip Low Of Purdue University
Stay updated with breaking news from Philip low of purdue university. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novosteo, Inc. s NOV004 has shown promise in live animals in the acceleration of fracture healing when delivered systemically. The compound is unique in that it concentrates at the fracture site while avoiding accumulation in the rest of the body. Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021. Bone injuries and disease are one of the most challenging health issues facing all ages, especially for the elderly. Despite the advent of preventive measures, one in three hip fracture patients who are 65 and older will die within a year; many deaths occur as a result of the complications due to slow fracture healing and long-term immobilization. ....
Research Bridge Partners' Portfolio Company, Novosteo, Inc., Closes $5.5 Million in Series A Financing prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
E-Mail IMAGE: The image shows fractured femurs at three weeks post-fracture. Yellow and orange colors indicate higher density bone than purple and blue and the green arrows point towards the fracture site.. view more Credit: Novosteo Inc. Novosteo Inc., a preclinical-stage biotechnology startup focused on the development of bone-targeted therapeutics, announced Thursday (February 4) the closing of a $5.5 million in Series A financing to advance its development of the first-ever targeted bone anabolic agent NOV004. The compound has shown promise in live animals in the acceleration of fracture healing when delivered systemically. NOV004 is unique in that it concentrates at the fracture site while avoiding accumulation in the rest of the body. Proceeds from the financing will be used to advance NOV004 into clinical development that will begin in the first half of 2021. ....
Date Time Share Bone treatment startup raises $5.5 M in Series A financing, names pharmaceutical leader William Boyle as CEO The image above shows fractured femurs at three weeks post-fracture. Yellow and orange colors indicate higher density bone than purple and blue and the green arrows point towards the fracture site. The “targeted” bone received Novosteo’s injectable-targeted drug, whereas the control bone did not receive drug, representing current therapies. Comparing the two bones, the additional bone growth caused by Novosteo’s drug could help people with fractures return to normal activity quickly in the future. (Image provided by Novosteo Inc.) ....